Abstract
The clinical characteristics of Alistipes bacteremia remain insufficiently described. Therefore, here, we retrospectively analyzed 13 cases of Alistipes bacteremia at a tertiary care center to evaluate their clinical and microbiological characteristics. Ten patients were aged ≥ 65 years, and seven were female. Nine patients had comorbidities, including seven with solid tumors or hematological malignancies. Eleven patients presented with gastrointestinal symptoms. The isolates included four Alistipes finegoldii, four Alistipes onderdonkii, three Alistipes putredinis, two Alistipes indistinctus, and one Alistipes ihumii isolates. Ten available strains exhibited low minimum inhibitory concentrations against β-lactam/β-lactamase inhibitors and metronidazole, whereas they exhibited high minimum inhibitory concentrations for penicillin, ceftriaxone, and minocycline. Several strains harbored antimicrobial resistance genes, including adeF, tet(Q), cfxA3, cfxA4, and erm(G). Twelve patients received β-lactam/β-lactamase inhibitors, and two elderly patients with solid tumors developed septic shock and died. Alistipes species can translocate from the gastrointestinal tract into the bloodstream, leading to severe infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Kameda Medical Center approved this study (agreement no. 23-121). Written informed consent was not required because the data used were anonymized.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
